
Source of Support: Nil, Conflict of Interest: None declared.

This PDF is available for free download from a site hosted by Medknow Publications (www.medknow.com).

ADVERSE DRUG REACTIONS IN NEPHROLOGY WARD INPATIENTS OF A TERTIARY CARE HOSPITAL

LISHA JOSHUA, PADMINI D. DEVI, SHOBA GUIDO

ABSTRACT

BACKGROUND: Adverse drug reactions (ADRs) are important causes of hospital admissions and inpatient complications. Renal dysfunction has a role in occurrence of ADRs. AIMS: (1) To study the characteristics of ADRs among inpatients in Nephrology ward of a tertiary care hospital and (2) to compare these characteristics between patients with renal dysfunction and patients with normal renal function in same population of patients with ADRs. MATERIALS AND METHODS: A retrospective study of inpatients with ADRs (July 2005-June 2006) in Nephrology ward of a tertiary care hospital. STATISTICAL ANALYSIS: ADR characteristics were analyzed using descriptive statistics. Comparisons were made between normal renal function group and renal dysfunction group by t-test and Chi-square test. RESULTS: Of 1,464 case records, 244 (17%) patients were included. Two hundred sixty-seven drugs contributed to 294 ADRs. Serious ADRs accounted for 12% of the total ADRs. Renal/ electrolyte system (44%) was the most common organ system involved. Major clinical spectrum of ADRs included acute renal failure (22%), hypo/ hyperglycemia (13%), hyper/ hypokalemia (13%), bone marrow suppression (5%) and hepatic injuries (4%). Prednisolone (12%) was the most commonly implicated drug. Mean time to revert was 13 ± 7.2 days. Three patients died. On comparing patients with normal renal function (n=80) with those suffering from renal dysfunction (n=164), polypharmacy, serious ADRs, multiple ADRs, longer time to recover, longer period of hospitalization were found to be more frequent among the renal dysfunction group (P < 0.05), with no difference in mortality between groups. CONCLUSIONS: High incidence of ADRs, especially serious and life-threatening ADRs, was noticed. A wide spectrum of ADRs was observed. Renal dysfunction showed a significant impact on various characteristics of ADRs.

Key words: Adverse drug reactions, polypharmacy, prednisolone, renal dysfunction, serious adverse drug reactions

An adverse drug reaction (ADR) as defined by World Health Organization (WHO) is a noxious, unintended effect of a drug, occurring at normal doses in humans for prophylaxis, diagnosis or therapy of disease or for the modification of physiological function.[1] ADRs are considered as the fourth to sixth leading cause of death among hospitalized patients.[2] About 2.9-
5.6% of all hospital admissions are caused by adverse related events, and approximately 35% of hospitalized patients experience an ADR. ADRs are associated with significant mortality, morbidity, permanent disability and are a huge economic burden on patients due to prolonged hospitalization.

Kidney is the primary route of elimination for drugs and their metabolites. It is important to determine the role of renal dysfunction in the occurrence of ADRs. Studies in India with regard to ADRs among hospitalized patients with renal dysfunction are limited. The objectives of this study were to (1) analyze the characteristics of ADRs among inpatients in the Nephrology ward of a tertiary care hospital and (2) compare these characteristics between patients with renal dysfunction and patients with normal renal function in the same population of patients with ADRs.

**MATERIALS AND METHODS**

This retrospective hospital-based study was conducted from 1st July 2005 to 30th June 2006 in the Nephrology ward of a superspecialty, tertiary care, teaching hospital. The case records of all the patients admitted to the Nephrology ward during the study period were obtained from the Medical Records Department and were screened for ADRs based on WHO definitions. Case records of patients who experienced ADRs during their hospital stay, as well as of those who were hospitalized due to ADRs, were identified by the first author and reconfirmed by the second author. Only certain and probable ADRs (based on WHO causality definitions) were included in the study.

The demographic, clinical and treatment data were collected from the inpatient case records using a specially designed pro forma which included age, gender, complete diagnoses, comorbid factors, serum creatinine, blood urea, serum albumin, duration of hospital stay and the outcome. Data collected on adverse drug reactions included drugs received, nature of ADR, drugs implicated, reaction time and time to revert, in accordance to the pro forma.

The patients with the diagnosis of ADRs (only certain and probable) were further subdivided into two groups based on their serum creatinine levels and estimated creatinine clearance (Crockfort and Gault equation) as defined below:

\[
\text{Estimated creatinine clearance (ml/min)} = \frac{(140 - \text{age})(\text{weight in kg})}{72} \times \text{serum creatinine}.
\]

For women, the result was multiplied by 0.85. Serum creatinine level up to 1.2 mg/dl, creatinine clearance of 120 ml/min/1.73 m² in men; (100 ml/min/1.73 m² in women) were considered as normal.

The two groups of patients with ADRs – patients with normal renal function (normal serum creatinine and creatinine clearance) and patients with renal dysfunction (serum creatinine levels over the normal range and creatinine clearance less than normal range) – were compared.

**Statistics**

The data collected were subjected to descriptive analyses to study the characteristics of ADRs. Results are expressed as percentages, mean + standard deviation for continuous parametric variables; and median and inter-quartile range (25-75% IQ) for continuous, nonparametric variables. Comparisons between the two groups were performed using Chi-square and t-test as appropriate. A P value of less than 0.05 was considered significant. All statistical analyses were performed with statistical software (SPSS 12.0 for Windows).

**RESULTS**

Of 1,464 admissions to the Nephrology ward during the study period, 244 (17%) were found to have ADRs. Among these 244 patients, 267 drugs were attributed to cause 294 adverse drug reactions, and 43 (18%) patients developed more than one ADR. The maximum number of ADRs noted was 4 - in 1 patient. According to the causality assessment, 4 ADRs were classified as ‘certain’ and 290 as ‘probable’ associations with the drug. It was found that 222 patients (91%) were receiving >5 drugs at the time of experiencing an ADR. The maximum number of drugs prescribed for a single patient was 18. Adults (18-65 years; 72%) were most affected by ADRs, followed by the elderly (>65 years; 26%). The male-to-female ratio was 1.7.

The analyses of clinical characteristics revealed that 131 (54%) patients had >4 comorbid factors in the diagnosis. The major comorbid conditions noticed in the study were hypertension 112 (46%), diabetes mellitus type 2 60 (26%), anemia 42 (17%), dyslipidemia 28 (12%) osteoarthritis 24 (10%), coronary artery disease 20 (8%) and lower respiratory tract infections 16 (7%). The maximum number of comorbid factors found in a single patient was 14.

The details of drug classes, respective organ systems involved and the total number of ADRs are presented in Table 1. The distribution of types of ADRs is presented in Table 2. The frequency of top seven drugs associated with ADRs is shown in Figure 1. Overall, the median reaction time (time taken for the reaction to occur after the last exposure to the suspected drug) of ADRs was 50 days (inter-quartile range 45-57), and the mean time taken for recovery was 13.4 ± 7.1 days.

The single drug found to be implicated in maximum number of ADRs in a single patient was prednisolone (four ADRs). The clinical spectrum of reactions caused by prednisolone included drug-induced hyperglycemia (25), infection (5), hypertension (3), psychosis (3), hypothalamo pituitary axis suppression (2), gastritis (2) and myopathies (3). The reaction time varied from 6 h to 2 months.

The ADRs attributed to diclofenac included acute renal failure (22), gastritis (4). The reaction time varied from 1 to 90 days. Nimesulide was suspected in 16 ADRs, and all were acute renal failure cases. The reaction time varied from 2 to 10 days. Enalapril was suspected in 16 reactions, which included hyperkalemia (14), hypotension (1) and dry cough (1), with a reaction time between 5 days and 2 months.

Of the total of 1,464 admissions to the Nephrology ward, serious ADRs were observed in 171 (12%) patients, which accounted for 58% of the total number of ADRs. Among these, 168 ADRs required hospitalization and 3 resulted in death. Of the 28 life-threatening ADRs, acute renal failure was the most common ADR (11%), followed by hyperkalemia (7), pancytopenia (7) and drug-induced hepatic injuries (3).
Table 1: Drug classes and respective major organ systems involved in adverse drug reactions

<table>
<thead>
<tr>
<th>Drug class</th>
<th>Number (%) of ADRs according to the organ systems involved (n=294)</th>
<th>Total number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-opioid analgesics</td>
<td>48 (16)</td>
<td>54 (18)</td>
</tr>
<tr>
<td>Steroids</td>
<td>2 (1)</td>
<td>38 (13)</td>
</tr>
<tr>
<td>Immunosuppressants</td>
<td>5 (2)</td>
<td>13 (4)</td>
</tr>
<tr>
<td>Cardiovascular drugs</td>
<td>30 (10)</td>
<td>46 (16)</td>
</tr>
<tr>
<td>Neurological drugs</td>
<td>3 (1)</td>
<td>7 (2)</td>
</tr>
<tr>
<td>Hematological drugs</td>
<td>3 (1)</td>
<td>7 (2)</td>
</tr>
<tr>
<td>Respiratory drugs</td>
<td>1 (1)</td>
<td>4 (1)</td>
</tr>
<tr>
<td>Others*</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Others †</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Type of adverse drug reaction | Number | %
--- | --- | ---
Acute renal failure | 64 | 22%
Hyperglycemia/hypoglycemia | 39 | 13%
Hypokalemia/hyperkalemia | 38 | 13%
Gastritis | 18 | 6%
Blood pressure changes | 16 | 5%
Gastrointestinal system | 30 (10) | 11%
Cardiovascular system | 14 (5) | 5%
Central nervous system | 4 (1) | 1%
Others † | - | -

Table 2: Distribution of major types of adverse drug reactions

Figure 1: Frequency of top seven drugs associated with ADRs

Out of the total 267 drugs implicated, 7 drugs belonged to herbal medications. Among the remaining 260 drugs, 228 (88%) were eliminated through the kidney. The most commonly implicated hydrophilic drugs were steroids 42 (18%), diuretics 22 (10%) and angiotensin converting enzyme inhibitors 15 (7%).

The mean hospital stay was 8.97 ± 4.9 days. Among the 244 patients, 3 (1.2%) patients died with ADRs as one of the causes of death, which accounted for 0.2% of the total admissions in the Nephrology ward. Among these, multiple ADRs were observed in 2 patients. The ADRs and the drugs suspected in these patients were prednisolone-induced hyperglycemia with hypothalamo-pituitary axis suppression; pancytopenia with antibiotic-induced diarrhea (induced by methotrexate and ciprofloxacin respectively); and fatal bleeding with acute renal failure and hyperglycemia induced by warfarin and prednisolone respectively.

Patients who experienced ADRs in the study (244) were further grouped into two groups based on the renal function: patients with normal renal function (n=80) and patients with renal dysfunction (n=164). The most common clinical diagnoses among patients with normal renal function included adult onset nephrotic syndrome 12 (15%), membranous glomerulopathy 12 (15%), recurrent urinary tract infection 8 (10%). The comparison of the main characteristics between the two groups of the patients with ADRs is shown in Table 3.

Among the patients with renal dysfunction, non-opioid analgesics (49/164; 30%) were the main drug class responsible for ADRs. Cardiovascular drugs were the second most common in this group, which resulted in 33 reactions (20%). However, steroids were the most common offenders in patients with normal renal function, causing 24 (30%) reactions. Diuretics and immunosuppressants were responsible for 13 reactions each (16%) among patients with normal renal function. No significant differences were noted in mortality between the two groups (P > 0.05). A prompt de-challenge of the offending drug was done in all the cases, and the patients were treated appropriately. Serious cases were effectively monitored and managed till discharge.

**DISCUSSION**

The occurrence of ADRs among hospitalized patients in this study was higher (17%) compared to those demonstrated in the published literature.[4] A majority of patients with renal dysfunction did not have any prior history of ADRs, whereas the main causes of renal dysfunction were glomerular diseases, which indicated that the ADRs were used as one of the causes of death.

Table 3: Comparison of characteristics of ADRs between patients with normal renal function and patients with renal dysfunction

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Group With normal renal function (n=80)</th>
<th>Group With abnormal renal function (n=164)</th>
<th>Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum creatinine (Mean ± SD)</td>
<td>1.1 ± 0.2 mg/dl</td>
<td>5.8 ± 2.9 mg/dl</td>
<td>t=14.246, CI 4.6 (4.01-5.3)</td>
</tr>
<tr>
<td>Serum albumin &lt;3.2 g/dl</td>
<td>33 (41)</td>
<td>59 (36)</td>
<td>P=0.5</td>
</tr>
<tr>
<td>&gt; 4 Diagnoses</td>
<td>30 (38)</td>
<td>101 (61)</td>
<td>CI 0.05 (-0.07-0.17)</td>
</tr>
<tr>
<td>&gt; 5 Prescribed drugs</td>
<td>68 (85)</td>
<td>154 (94)</td>
<td>P=0.023</td>
</tr>
<tr>
<td>&gt; One ADR per patient (multiple ADRs)</td>
<td>9 (11)</td>
<td>34 (21)</td>
<td>CI 0.24 (0.01-0.46)</td>
</tr>
<tr>
<td>Serious ADRs</td>
<td>48 (60)</td>
<td>123 (75)</td>
<td>P&lt;0.05, CI 0.18 (-0.0-0.37)</td>
</tr>
<tr>
<td>Time to revert (Mean ± SEM)</td>
<td>8.8 ± 0.5 days</td>
<td>15.7 ± 0.9 days</td>
<td>t=14.246, CI 6.9 (4.2-9.5)</td>
</tr>
<tr>
<td>Hospital stay (Mean ± SEM)</td>
<td>7.5 ± 0.7 days</td>
<td>9.7 ± 0.6 days</td>
<td>P=0.001, CI 2.2 (0.25-4.14)</td>
</tr>
</tbody>
</table>

SD - Standard deviation; SEM - Standard error of mean; CI - Confidence interval; df - Degree of freedom; Figures in parentheses indicate percentage
affected by ADRs were from the adult population (19-65 years; 72%), compared to the elderly (>65 years; 26%). This finding differed from reports of other studies. Women have been reported to be at greater risk for ADRs. However, in this study a male preponderance was noticed. A majority of patients who experienced an ADR had renal dysfunction (67%), and a higher incidence of renal dysfunction among male patients has already been documented.

The two important predisposing factors for the occurrence of ADRs observed in this study were extensive polypharmacy (91% receiving >5 drugs) and comorbidities (54%). These findings were found to be significantly higher among patients with renal dysfunction, similar to a previous study. Polypharmacy is linked to many drug-related problems, especially ADRs. Patients with multiple comorbid factors (54%) were found to be more in this study compared to previous Indian studies (8%). Concurrent comorbidities such as hypertension (46%), diabetes (28%), anemia (17%), and dyslipidemia (12%) could result in polypharmacy and lead to the occurrence of ADRs.

In this study, occurrence of serious ADRs (12%) and multiple ADRs (18%) seems to be higher compared to that cited in previously published reports. A wide spectrum of life-threatening ADRs, including acute renal failure, hyperkalemia, pancytopenia and hepatic injuries, was also noticed.

The most common organ system associated with ADRs was renal/ electrolyte system (44%), similar to the study conducted by Gurwitz et al., but differing from a previous north Indian study, where cutaneous reactions were the highest.

Non-opioid analgesics were implicated in a majority of ADRs (18%). A previous Indian study had documented aminoglycosides (48%) as the most common offenders in hospital-acquired renal failure. The majority of the implicated drugs in this study were eliminated through kidney (87%) and were more frequent among patients with renal dysfunction. This suggests the need to increase the awareness with regard to prescription of hydrosoluble drugs among patients with renal dysfunction.

More than four comorbid factors (61%), polypharmacy (94%) and length of hospital stay (9.72 ± 0.6 days) were significantly higher in patients with renal dysfunction [Table 3], similar to a previous study. Multiple ADRs (21%), serious ADRs (75%) and time taken to recover from ADRs were also higher in patients with renal dysfunction.

Mortality due to ADRs was 0.2% of the total admissions, similar to a previous study. The three deaths observed in the study were related to prednisolone-induced hyperglycemia – with hypothalamo-pituitary axis suppression in one patient; pancytopenia with antibiotic-induced diarrhea (induced by metronidazole and ciprofloxacin respectively) in one patient; and fatal bleeding with acute renal failure and hyperglycemia induced by warfarin and prednisolone respectively in one patient.

Some limitations are inherent in retrospective studies. When more than one drug was implicated and de-challenged simultaneously, it was difficult to calculate the incidence of individual implicated drugs. Although we were unable to collect the relevant data of 1,464 patients admitted to the Nephrology ward, we have compared the characteristics of ADRs between patients with normal renal function and those with renal dysfunction in the study population who experienced ADRs. Estimation of GFR or direct measurement of GFR was not performed. However, Cockcroft-Gault formula was used to assess the renal function uniformly for the entire study population.

In conclusion, occurrence of ADRs was found to be higher, especially that of serious ADRs, compared to that reported in previous studies. Older hospitalized patients with renal dysfunction were exposed to increased ADRs, especially to hydrosoluble drugs. Renal dysfunction plays a significant role in occurrence of serious and multiple ADRs. Polypharmacy, comorbidity and longer hospital stay were more frequent in patients with renal dysfunction. Developing newer strategies to report and monitor ADRs, especially to hydrosoluble drugs, in patients with renal dysfunction is highly essential to ensure safe pharmacotherapy.

ACKNOWLEDGMENTS

We acknowledge the help of the staff of the Medical Records Department in carrying out the study.

REFERENCES

13. Viktil KK, Blix HS, Moger TA, Rekvam A. Polypharmacy as commonly defined is an
ATYPICALITY IN PRESENTATION OF NEUROLEPTIC MALIGNANT SYNDROME CAUSED BY OLANZAPINE

BISWARANJAN MISHRA, BAIKUNTHANATH MISHRA*, SADDICHHA SAHOO, MANU ARORA, C. R. J. KHESS

ABSTRACT

Neuroleptic malignant syndrome (NMS) is the most serious of acute neurological side effects produced by antipsychotic medication, characterized by hyperthermia, rigidity, altered consciousness and autonomic dysfunction, the prevalence of which varies from 0.4-1.4%. NMS is usually seen in treatment with high potency typical antipsychotics and very rarely with atypical antipsychotics. However, NMS cases have been reported with risperidone, clozapine, olanzapine and quetiapine. The presentations of NMS have often varied, and we report another atypicality in presentation of NMS due to olanzapine use.

Key words: Amantadine, electroconvulsive therapy, neuroleptic malignant syndrome, olanzapine

INTRODUCTION

Neuroleptic malignant syndrome (NMS) is the most serious of acute neurological side effects produced by antipsychotic medications, characterized by hyperthermia, rigidity, altered consciousness and autonomic dysfunction,[1] the prevalence of which varies from 0.4-1.4%.[2] NMS is usually seen in treatment with high potency typical antipsychotics and very rarely with atypical antipsychotics.[3] However, NMS cases have been reported with risperidone,[4] clozapine,[4] olanzapine,[4,5] and quetiapine.[6]

We report another atypicality in presentation of NMS due to olanzapine use.

CASE REPORT

A 21-year-old male, was diagnosed as mania with psychotic symptoms, drug naïve on admission, was initially treated for 3 days with injectable haloperidol 10 mg intramuscular b.i.d. for the control of agitation and aggressive behavior. He had no past history of any psychiatric or medical illness. He was subsequently started on oral olanzapine 10 mg. However, on the seventh day of treatment with Olanzapine, he was found to have fever (temperature 98.4-99.6°F.), tachycardia (pulse rate: 100-120/min, regular), blood pressure fluctuations (150-110 SBP/ 80-100...